Compagnie Financière Tradition (SWX:CFT) has released its 2025 Annual Report, providing full-year financial and operational details. The report includes management commentary, business updates, and risk disclosures that go beyond headline numbers. Investors now have a more complete set of information to review the company at a share price of CHF265.0. For anyone tracking SWX:CFT, this report lands after a mixed share price performance over shorter periods and a strong longer term run. The...

Compagnie Financière Tradition (SWX:CFT) is drawing attention this week after its shares delivered another bump, adding to this year’s steady climb. While today’s moves may not be tied to headline-grabbing news, investors are left wondering if the recent rally is a meaningful signal or just another step in a longer-term trend. After all, markets tend to re-evaluate stocks even in the absence of a clear catalyst, making moments like this worth a closer look. Zooming out, Compagnie Financière...

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.